Stay tuned for some Peak deals coming soon!
Market Highlights
ASX 200 futures are pointing down 47 points or 0.5 per cent to 8683.
All US prices near 4.25pm New York time.
- AUD +0.5% to US71.53¢
- Bitcoin +0.3% to $US70,453
- On Wall St: Dow -0.6% S&P -0.08% Nasdaq +0.08%
- VIX -0.65 to 24.28
- Gold -0.3% to $US5177.43 an ounce
- Brent oil +5.6% to $US92.74 a barrel
- Iron ore +0.5% to $US104.25 a tonne
- 10-year yield: US 4.22% Australia 4.85%
Across Markets…
Australian shares are poised to open down. The S&P 500 closed modestly lower as investors struggled to position amid President Donald Trump’s ever-changing war rhetoric.
While market sentiment was boosted earlier by a decision by the IEA to release a historic 400 million barrels from emergency oil reserves, Trump said the US and Israel have not yet finished hitting Iran. Iran also listed three terms it requires for the war to end, including payment of reparations.
ASX 200 futures were pointing down 47 points or 0.5 per cent to 8683 near 7.25am AEDT. The S&P 500 was 0.1 per cent lower; consumer staples paced eight of its 11 industry sectors down. Volatility declined. Oil was 5.6 per cent higher, though relatively steady compared with swings earlier this week.
The US February CPI report, which showed core inflation eased slightly as expected, was mostly dismissed given an expected lift in a range of prices because of the war.
Consumer prices are poised to rise as much as 3 per cent this month from a year ago, one economist said. That could keep the Federal Reserve on the rate sidelines until even later in the year.
Oracle surged 9.2 per cent after the software and cloud services company reported strong quarterly sales and issued an outlook that suggests little letup in demand for AI computing.
Nvidia edged 0.7 per cent higher after agreeing to invest $US2 billion in Nebius Group as part of a strategic partnership to develop and build artificial intelligence data centres. The US-listed shares of Nebius leapt 16.2 per cent.
Source: AFR
Rhythm is in the groove with first commercial sale of its bowel cancer assay
- Rhythm’s long quest to develop better bowel cancer test starts to reap financial rewards
- Imugene goes to the well after promising blood cancer trial results
- Adherium says its asthma monitoring tool reduces hospitalisations
Medical diagnostics house Rhythm Biosciences (ASX:RHY) says it is now ready to scale operations after achieving first commercial sales of its revolutionary blood-based bowel cancer detection kit, Colostat.
“The full end-to-end clinical pathway – from blood draw at a collection site through to result delivery to the ordering clinician – has now been successfully completed in a routine clinical setting,” the company said today.
Intended for patients with potential bowel cancer symptoms or a screening tool, Colostat has the potential to replace the standard of care faecal ‘poo’ test.
The first patient’s blood samples were collected by the company’s commercial partner, 4Cyte Pathology and processed at Rhythm’s laboratory in Parkville, Melbourne.
The results were reported to the ordering clinician, who will be invoiced directly.
The company said the tests showed that Colostat’s “full operating pathway” was “functioning effectively within a routine clinical setting”.
This includes sample collection, logistics, assay processing and result reporting .
The process can be integrated into existing workflows and is a “scalable revenue-generating testing service”.
“Structured” route to market
Rhythm’s attention now turns to expanding test volumes via GPs.
Last month Rhythm announced the Colostat Access Program, which provides a “structured entry point” for clinicians to order the test.
To date five Victorian and NSW clinics are participating.
Rhythm CEO Dr David Atkins dubs the first commercial sale as an “important operational milestone” for the company.
“We have the infrastructure, the logistics and the partnerships in place to scale from here and we look forward to reporting on test volume growth in the coming months.”
Source: Stockhead
Company: Fin Resources Ltd (ASX:FIN)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.0065
Performance Since Entry: +115%
Company: Eden Innovations Ltd (ASX:EDE)
Sector: Construction/Clean Energy
Deal Type: Shortfall
Latest Entry Price: $0.035 with 1:2 option, strike $0.07
Price Performance Since Entry: +343%
Company: Tasman Resources Ltd (ASX:TAS)
Sector: Gold/Silver/Mining
Deal Type: Placement
Latest Entry Price: $0.0125 with 1:2 option, strike $0.02
Price Performance Since Entry: +380%
Company: Locksley Resources Ltd (ASX:LKY)
Sector: REE & Antimony/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Price Performance Since Entry: +350%
Company: CuFe Ltd (ASX:CUF)
Sector: Copper/Mining
Deal Type: Placement
Latest Entry Price: $0.016 with 1:2 option, strike $0.025
Price Performance Since Entry: +181%
Company: Tambourah Metals Ltd (ASX:TMB)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Price Performance Since Entry: +45%
Company: Biotron Ltd (ASX:BIT)
Sector: Biotech
Deal Type: Placement
Latest Entry Price: $0.003 with 1:2 option, strike $0.02
Price Performance Since Entry: 0%
Company: Eclipse Metals Ltd (ASX:EPM)
Sector: REE
Deal Type: Placement
Latest Entry Price: $0.015
Price Performance Since Entry: +27%
Company: Neuren Pharmaceuticals Ltd (ASX:NEU)
Sector: Biotech
Deal Type: On-market purchase
Latest Entry Price: $1.20 – $1.50
Price Performance Since Entry: +1,135%
Company: Dimerix Ltd (ASX:DXB)
Sector: Biotech
Deal Type: Rights Issue
Raise Amount: $800,000
Latest Entry Price: $0.08 with 1:1 option, strike $0.126
Price Performance Since Entry: +350%
Company: Noviqtech Ltd (ASX:NVQ)
Sector: Blockchain
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.02 with 1:1 option $0.08 strike
Price Performance Since Entry: +10%
Company: Critica Limited (ASX:CRI)
Sector: REE
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.0075 with a 1:1 CRIO
Price Performance Since Entry: +247%
Company: Patagonia Lithium Ltd (ASX:PL3)
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.09 with 1:2 PL3O
Price Performance Since Entry: +44%
Company: Kalgoorlie Gold Mining Ltd (ASX:KAL)
Sector: Gold/Mining
Deal Type: Placement
Raise Amount: $2.3M
Latest Entry Price: $0.026 with 1:2 option $0.032 strike
Price Performance Since Entry: +54%
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
Comments are closed